Dr Millicent Elaine Wilson, MD | |
245 S Fetterly Ave, East Los Angeles, CA 90022-1605 | |
(323) 362-1400 | |
(323) 362-1373 |
Full Name | Dr Millicent Elaine Wilson |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Location | 245 S Fetterly Ave, East Los Angeles, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558879296 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | G079177 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Millicent Elaine Wilson, MD 10100 Pioneer Blvd Ste 200, Santa Fe Springs, CA 90670-8299 Ph: (562) 347-1648 | Dr Millicent Elaine Wilson, MD 245 S Fetterly Ave, East Los Angeles, CA 90022-1605 Ph: (323) 362-1400 |
News Archive
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is the subject of a new research report issued by Emerging Growth Research, LLP.
A vaginal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.
Justices appeared divided over this case, which involves both issues of religious freedoms and a provision of the health overhaul.
Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.
With negotiations over the outcomes for the U.N. High-level Meeting on Non-Communicable Diseases (NCDs) stalled, "[i]t is feared that sound proposals for clear goals and timelines to tackle these devastating diseases are being systematically deleted, diluted and downgraded by some U.N. Member States and urgent action is needed to put the negotiations back on track, when they recommence on September 1," Rob Moodie, chair of Global Health at the Nossal Institute of Global Health, writes in the Crikey health blog "Croakey."
› Verified 2 days ago